home / stock / ensc / ensc quote
Last: | $0.575 |
---|---|
Change Percent: | 3.93% |
Open: | $0.562 |
Close: | $0.575 |
High: | $0.6 |
Low: | $0.56 |
Volume: | 32,462 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.575 | $0.562 | $0.575 | $0.6 | $0.56 | 32,462 | 05-31-2024 |
$0.585 | $0.605 | $0.585 | $0.605 | $0.5589 | 218,611 | 05-30-2024 |
$0.6 | $0.59 | $0.6 | $0.61 | $0.55 | 107,048 | 05-29-2024 |
$0.575 | $0.58 | $0.575 | $0.595654 | $0.562 | 61,372 | 05-28-2024 |
$0.57 | $0.6 | $0.57 | $0.61 | $0.53 | 111,371 | 05-27-2024 |
$0.57 | $0.6 | $0.57 | $0.61 | $0.53 | 111,371 | 05-24-2024 |
$0.5888 | $0.617 | $0.5888 | $0.6468 | $0.5601 | 232,214 | 05-23-2024 |
$0.6368 | $0.6896 | $0.6368 | $0.69 | $0.63 | 107,448 | 05-22-2024 |
$0.68 | $0.72 | $0.68 | $0.7477 | $0.666 | 159,317 | 05-21-2024 |
$0.739 | $0.63 | $0.739 | $0.75 | $0.62 | 803,815 | 05-20-2024 |
$0.624 | $0.63 | $0.624 | $0.6499 | $0.6158 | 132,059 | 05-17-2024 |
$0.63 | $0.605 | $0.63 | $0.65 | $0.58 | 241,918 | 05-16-2024 |
$0.6121 | $0.54 | $0.6121 | $0.6191 | $0.54 | 543,334 | 05-15-2024 |
$0.55545 | $0.59 | $0.55545 | $0.599999 | $0.53 | 331,235 | 05-14-2024 |
$0.585 | $0.55 | $0.585 | $0.59 | $0.55 | 343,443 | 05-13-2024 |
$0.524 | $0.56 | $0.524 | $0.56 | $0.512 | 83,831 | 05-10-2024 |
$0.5415 | $0.5603 | $0.5415 | $0.5779 | $0.5415 | 61,279 | 05-09-2024 |
$0.5611 | $0.57 | $0.5611 | $0.595 | $0.55 | 93,830 | 05-08-2024 |
$0.5728 | $0.59 | $0.5728 | $0.595 | $0.556 | 82,925 | 05-07-2024 |
$0.566 | $0.59 | $0.566 | $0.5999 | $0.5501 | 68,074 | 05-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ensysce Biosciences Inc. Company Name:
ENSC Stock Symbol:
NASDAQ Market:
New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPAR SAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutio...
PF614's Phase 3 Clinical Plans Affirm the Path to Regulatory Approval FDA Breakthrough Therapy Designation of PF614-MPAR Expedites Clinical Program SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmac...
~ Dr. Kirkpatrick Leads the Company's Unique Response to Effectively Reduce Prescription Drug Overdose and Abuse ~ SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative...